71.37% percent quarterly performance for Spyre Therapeutics Inc (SYRE) is not indicative of the underlying story

Steve Mayer

A new trading day began on Monday, with Spyre Therapeutics Inc (NASDAQ: SYRE) stock price up 7.15% from the previous day of trading, before settling in for the closing price of $30.61. SYRE’s price has ranged from $10.91 to $35.31 over the past 52 weeks.

Healthcare Sector giant saw their annual sales surged by 44.65% over the last five years. Meanwhile, its annual earnings per share averaged 35.16%. With a float of $67.53 million, this company’s outstanding shares have now reached $77.59 million.

Spyre Therapeutics Inc (SYRE) Insider Activity

As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Spyre Therapeutics Inc is 12.99%, while institutional ownership is 77.26%. The most recent insider transaction that took place on Jan 02 ’26, was worth 460,134. In this transaction Chief Executive Officer of this company sold 15,000 shares at a rate of $30.68, taking the stock ownership to the 671,907 shares. Before that another transaction happened on Dec 01 ’25, when Company’s Chief Executive Officer sold 15,000 for $29.02, making the entire transaction worth $435,356. This insider now owns 686,907 shares in total.

Spyre Therapeutics Inc (SYRE) Earnings and Forecasts

In its latest quarterly report, released on 12/31/2024, the company reported earnings of -0.81 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.68 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 35.16% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -0.65% during the next five years compared to 44.65% growth over the previous five years of trading.

Spyre Therapeutics Inc (NASDAQ: SYRE) Trading Performance Indicators

Here are Spyre Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 10.90.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.18, a number that is poised to hit -0.70 in the next quarter and is forecasted to reach -2.87 in one year’s time.

News Daemon
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.